Skip to main content

Share story

Products

Zuckerberg directs Meta to explore partnerships with Polymarket and Kalshi while building prediction markets app

Mark Zuckerberg has urged Meta executives to explore partnerships with Polymarket and Kalshi as the company builds a prediction markets app called Arena, three employees with knowledge of the matter said. The New York Times reported that Zuckerberg has made Arena a top priority. The app will use video game like points instead of real money wagers used by Polymarket and Kalshi. It is unclear how partnerships might work. Zuckerberg plans for Arena to target users ages 18 to 34 and reach at least 100 million monthly active predictors. The app would allow bets on sports, culture, entertainment, politics and finance against friends and family. Executives have called it an app designed for everyone. Ime Archibong, a Meta vice president of product leading the Arena initiative, said in an internal post last month introducing the app: We believe that prediction markets are one of the more interesting new content types. With the right containers, the social conversation is the payoff as people aim to show off how good they are at predicting things to their friends. Meta, Polymarket and Kalshi declined to comment.
Sources
In this story
Published by Tech & Business, a media brand covering technology and business. This story was sourced from The New York Times and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Capital
Capital

Nominal raises $240 million at a $3 billion valuation

Nominal has raised $240 million at a $3 billion valuation, triple its valuation in a funding round earlier this year, Bloomberg reports. The startup builds software to make manufacturing more efficient.

Capital Products
Capital Products

Onodrim raises $300M to acquire European defence and industrial suppliers

Amsterdam-based Onodrim Industries has raised $300M in a round led by Lux Capital, valuing the defence group at $1.3bn, the company said Monday. Other investors include General Catalyst, Lakestar and Altimeter. The financing follows its €40M seed round in February.

Capital
Capital

SRTD Biotech raises €31.5 million for targeted RNA therapies

SRTD Biotech has completed an oversubscribed €31.5 million seed financing to develop RNA therapies designed to act selectively inside diseased cells. Mérieux Equity Partners led the round, with NRW.BANK and Boehringer Ingelheim Venture Fund joining as co-leads.